Alkem Laboratories’ latest drug launch promises relief for millions of diabetics in India
Alkem Laboratories Limited has launched its generic version of empagliflozin and its combinations in India under the brand name Empanorm, offering a significant price reduction ... Read More
Fresenius Medical Care sells laboratory assets to Quest Diagnostics in strategic portfolio shift
Fresenius Medical Care has announced the sale of select laboratory assets to Quest Diagnostics as part of a broader strategy to optimize its operations and ... Read More
Zydus and CSIR-CDRI launch collaborative research for new CKD-induced osteoporosis treatment
Zydus Lifesciences Ltd and CSIR-Central Drug Research Institute (CDRI) have joined forces to develop an innovative drug targeting osteoporosis induced by chronic kidney disease (CKD). ... Read More
Novo Nordisk faces setback as CLARION-CKD trial fails, leading to significant financial impairment
Novo Nordisk, a global leader in pharmaceuticals, has announced a major setback as its CLARION-CKD phase 3 trial failed to meet its primary endpoint, prompting ... Read More
FDA approves Akebia Therapeutics’ Vafseo for anemia in dialysis patients
In a significant development for the treatment of anemia related to chronic kidney disease (CKD) in dialysis patients, Akebia Therapeutics, Inc. (Nasdaq: AKBA), a pioneering ... Read More
Bayer and Sun Pharma join forces for new brand of Finerenone in India
In a significant development for the Indian healthcare sector, Sun Pharmaceutical Industries Limited and Bayer have announced a collaborative agreement to market and distribute a ... Read More
Boehringer Ingelheim’s BI 690517 shows up to 39.5% albuminuria reduction in Phase II trial
Boehringer Ingelheim has revealed promising results from its 14-week Phase II trial for BI 690517, a novel selective aldosterone synthase inhibitor. The data highlights a ... Read More
Innovative CKD management: AstraZeneca’s Zibotentan/Dapagliflozin advances to Phase III
Recent findings from the ZENITH-CKD Phase IIb trial, conducted by AstraZeneca, have demonstrated a significant decrease in albuminuria among CKD patients treated with a combination ... Read More
Zydus Lifesciences, Sun Pharma to co-market Desidustat for CKD patients in India
Zydus Lifesciences Limited and Sun Pharmaceutical Industries Limited have announced a licensing agreement for the co-marketing of Desidustat, an innovative oral anemia treatment for Chronic ... Read More
Jardiance receives FDA approval to tackle kidney disease and cardiovascular risks
The U.S. Food and Drug Administration (FDA) has granted approval for Jardiance (empagliflozin) 10 mg tablets, a significant development announced jointly by Boehringer Ingelheim and ... Read More